CompletedPhase 1NCT01578720
Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome
Studying Histoplasmosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Retina Research Institute, LLC
- Principal Investigator
- Kevin J Blinder, MDThe Retina Institute
- Intervention
- EYLEA (Aflibercept) intravitreal injection(drug)
- Enrollment
- 5 target
- Eligibility
- 21 years · All sexes
- Timeline
- 2012 – 2015
Study locations (1)
- The Retina Institute, St Louis, Missouri, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01578720 on ClinicalTrials.govOther trials for Histoplasmosis
Additional recruiting or active studies for the same condition.